Baker J, Summers R
Handb Exp Pharmacol. 2024; 285:55-145.
PMID: 38926158
DOI: 10.1007/164_2024_713.
Wong Y, Haqqani H, Molenaar P
Handb Exp Pharmacol. 2024; 285:247-295.
PMID: 38844580
DOI: 10.1007/164_2024_720.
Etana D, Nebiyu A
Heliyon. 2023; 9(4):e15176.
PMID: 37101623
PMC: 10123207.
DOI: 10.1016/j.heliyon.2023.e15176.
Noonan T, Denzinger K, Talagayev V, Chen Y, Puls K, Wolf C
Pharmaceuticals (Basel). 2022; 15(11).
PMID: 36355476
PMC: 9695541.
DOI: 10.3390/ph15111304.
Wade C, Wells J
Expert Rev Respir Med. 2020; 14(7):671-678.
PMID: 32250198
PMC: 7365250.
DOI: 10.1080/17476348.2020.1752671.
Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology.
Agesen F, Weeke P, Tfelt-Hansen P, Tfelt-Hansen J
Pharmacol Res Perspect. 2019; 7(4):e00496.
PMID: 31338197
PMC: 6624454.
DOI: 10.1002/prp2.496.
Elevated endothelial Sox2 causes lumen disruption and cerebral arteriovenous malformations.
Yao J, Wu X, Zhang D, Wang L, Zhang L, Reynolds E
J Clin Invest. 2019; 129(8):3121-3133.
PMID: 31232700
PMC: 6668698.
DOI: 10.1172/JCI125965.
Rhodium(III)-Catalyzed [4+2] Annulation via C-H Activation: Synthesis of Multi-Substituted Naphthalenone Sulfoxonium Ylides.
Song X, Han X, Zhang R, Liu H, Wang J
Molecules. 2019; 24(10).
PMID: 31100874
PMC: 6572249.
DOI: 10.3390/molecules24101884.
ACT-ONE - ACTION at last on cancer cachexia by adapting a novel action beta-blocker.
Lainscak M, Laviano A
J Cachexia Sarcopenia Muscle. 2016; 7(4):400-2.
PMID: 27625919
PMC: 5011815.
DOI: 10.1002/jcsm.12136.
Balloon Angioplasty - The Legacy of Andreas Grüntzig, M.D. (1939-1985).
Barton M, Gruntzig J, Husmann M, Rosch J
Front Cardiovasc Med. 2015; 1:15.
PMID: 26664865
PMC: 4671350.
DOI: 10.3389/fcvm.2014.00015.
The ins and outs of adrenergic signaling.
Lohse M
J Mol Med (Berl). 2015; 93(9):955-62.
PMID: 26199112
DOI: 10.1007/s00109-015-1323-x.
Synthesis and in vitro and in vivo characterization of highly β1-selective β-adrenoceptor partial agonists.
Mistry S, Baker J, Fischer P, Hill S, Gardiner S, Kellam B
J Med Chem. 2013; 56(10):3852-65.
PMID: 23614528
PMC: 3694353.
DOI: 10.1021/jm400348g.
The impact of therapeutic reference pricing on innovation in cardiovascular medicine.
Sheridan D, Attridge J
Pharmacoeconomics. 2013; 24 Suppl 2:35-54.
PMID: 23389487
DOI: 10.2165/00019053-200624002-00005.
Ro 3-4787, a new β-adrenoceptor blocking agent: Studies in normal volunteers.
Kilborn J, Turner P
Br J Clin Pharmacol. 2012; 1(2):143-9.
PMID: 22454901
PMC: 1402459.
DOI: 10.1111/j.1365-2125.1974.tb00223.x.
The assessment of β-adrenoceptor blocking drugs in hyperthyroidism.
Carruthers S, Ghosal A, McDevitt D, Nelson J, Shanks R
Br J Clin Pharmacol. 2012; 1(2):93-8.
PMID: 22454894
PMC: 1402445.
DOI: 10.1111/j.1365-2125.1974.tb00216.x.
Some effects of Kö 1313 in animals and man.
Ekue J, Shanks R
Br J Clin Pharmacol. 2012; 1(1):27-35.
PMID: 22454865
PMC: 1402416.
DOI: 10.1111/j.1365-2125.1974.tb00202.x.
Associating Drugs, Targets and Clinical Outcomes into an Integrated Network Affords a New Platform for Computer-Aided Drug Repurposing.
Oprea T, Nielsen S, Ursu O, Yang J, Taboureau O, Mathias S
Mol Inform. 2012; 30(2-3):100-111.
PMID: 22287994
PMC: 3266123.
DOI: 10.1002/minf.201100023.
Improved fluorimetric assay of plasma propranolol.
Offerhaus L, van der Vecht J
Br J Clin Pharmacol. 2012; 3(6):1061-2.
PMID: 22216531
PMC: 1428966.
DOI: 10.1111/j.1365-2125.1976.tb00359.x.
Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses.
Baker J, Kemp P, March J, Fretwell L, Hill S, Gardiner S
FASEB J. 2011; 25(12):4486-97.
PMID: 21865315
PMC: 3371235.
DOI: 10.1096/fj.11-192435.
Analytical and experimental pharmacology, challenges ahead.
Salomone S
Front Pharmacol. 2011; 1:119.
PMID: 21734890
PMC: 3124228.
DOI: 10.3389/fphar.2010.00119.